

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450
Alexandria, VA 22313 on January 18, 2006

Frank C. Eisenschenk

Frank C. Eisenschenk, Ph.D., Patent Attorney

1632
TFW

INFORMATION DISCLOSURE
STATEMENT

Examining Group 1632
Patent Application
Docket No. ARS-107
Serial No. 10/530,104

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1632
Applicants : Mark Ibberson, Christine Power, Achim Frauenschuh
Serial No. : 10/530,104
Filed : April 1, 2005
Conf. No. : 9640
For : Novel Chemokine-Like Polypeptides

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313


INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.97 AND 1.98

Sir:

The patent application referred to above was filed in the U.S. Patent Office as a national application under 35 USC §371. Applicants have been notified that a copy of the International Search Report has been made available in the national stage file as indicated on the Notice of Acceptance of the Application Under 35 USC 371 (Form PCT/DO/EO/903). The Notice does not indicate whether copies of the references cited in the International Search Report were received by the Patent Office. Therefore, copies of the references cited in the International Search Report are enclosed for the Examiner's convenience. In accordance with 37 CFR §1.56, Applicants hereby request that the references cited in the International Search Report and listed on the attached form PTO/SB/08 be made of record and considered in the examination of the subject application.

Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950

Gainesville, FL 32614-2950

FCE/sl

Attachments: Form PTO/SB/08; copies of cited references.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	10/530,104
Filing Date	April 1, 2005
First Named Inventor	Mark Ibberson
Group Art Unit	1632
Examiner Name	unknown
Attorney Docket Number	ARS-107

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	BAGGIOLINI, M. "Chemokines in pathology and medicine" <i>Journal of Internal Medicine</i> , August 2001, pp. 91-104 Vol. 250, No. 2	
	R2	WELLS, T. N. C. <i>et al.</i> "The chemokine information source: identification and characterization of novel chemokines using the WorldWideWeb and Expressed Sequence Tag Databases" <i>Journal of Leukocyte Biology</i> , May 1997, pp. 545-550, Vol. 61.	
	R3	HAN, W. <i>et al.</i> "Molecular cloning and characterization of chemokine-like factor 1 (CKLF1), a novel human cytokine with unique structure and potential chemotactic activity" <i>Biochemical Journal</i> , 2001, pp. 127-135, Vol. 357, No. 1.	
	R4	Database EMBL 'Online!', June 26, 2001, Accession No. AAB93409, XP-002231850, Ota, T. <i>et al.</i> "Human protein sequence SEQ ID NO:12610".	
	R5	Database EMBL 'Online!' HTG, March 7, 2000, Accession No. AL159154, XP-002231616, Bates, K. <i>et al.</i> "Human DNA sequence from clone RP11-428G23 on chromosome 13".	
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.